Home/Allgemein

INOFEA successfully closed its Series B financing round

INOFEA successfully closed its Series B financing round


16/11/2020

Muttenz, Switzerland, Nov. 16, 2020: End of September 2020 INOFEA AG executed the successful closure of its recent financing round Series B. “It was amazing to see that we have been able to oversubscribe our target, both with the support of existing and also of new shareholders”, said the CEO, Dr. Anne Timm. “The entire INOFEA Team and our Board are proud of this important milestone and we thank our investors who made this happen.” INOFEA will use its investment to grow its market position, mainly in the Pharma and Food segment. The constant growth of the customer base demonstrates the value of the technology in the white biotech sector. INOFEA’s clients are particularly in favour of the technology as it supports raw material, energy and cost savings when used in continuous manufacturing processes. The unique technology makes enzymes up to 20-35 times more stable and reusable. This supports a valuable contribution to the sustainability targets of the industry. INOFEA is in the process to file new patents, has a supply agreement, multiple research agreements and a license agreement in place. Beside Biocatalysis the company focuses on the market of diagnostics (biomarkers) where the enzzen®-enzyme technology makes complicated and for the patient painful biopsies obsolete. INOFEA is expanding its team, both on the technical and commercial side and an industry-seasoned dedicated Business Development Manager has been hired. This will enable the ambitious growth aspirations of the company in the coming years. INOFEA invites companies in the industry who are actively looking for enzymatic solutions for Biocatalysis and Diagnostics to enter into partnerships for the development of robust and recyclable enzymes.
INOFEA successfully closed its Series B financing round2020-11-16T07:55:53+00:00

INOFEA welcomes Nilesh Shah as Business Development Manager

INOFEA welcomes Nilesh Shah as Business Development Manager


01/10/2020

On 1st of October, Nilesh Shah took over the responsibility as Business Development Manager at INOFEA. His main duties will be to accelerate the revenue growth of our company and thus significantly contribute to the company’s strategy to strengthen our market position in the Food and Pharma industry. Nilesh will also strengthen our marketing activities to increase the awareness of the company. Nilesh has a long success track in business development and sales- & key account management in the Pharma- and Biopharmaceutical industries. His activities comprised as well customer acquisitions, contract negotiations and project management leading to new business opportunities with additional highly profitable revenues.
INOFEA welcomes Nilesh Shah as Business Development Manager2020-10-06T13:27:01+00:00

INOFEA announces the conclusion of a purchase and delivery contract with UCB

INOFEA announces the conclusion of a purchase and delivery contract with UCB


15/04/2020

The Swiss biotech and the international pharmaceutical company UCB are planning a long-term cooperation in the field of stabilized enzymes.
INOFEA announces the conclusion of a purchase and delivery contract with UCB2020-11-23T10:02:36+00:00